Conference
Earn CE
Free Samples
Magazine
Subscribe
Videos
Solutions Lab
Macro/Op-Ed
Practice
Science & Tech
Money
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Dental Market Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
COMPASS Pathways Plc - American Depository Shares
(NQ:
CMPS
)
7.640
-0.260 (-3.29%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 29, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about COMPASS Pathways Plc - American Depository Shares
< Previous
1
2
3
Next >
The Next Great Biotech Boom Has Arrived
March 19, 2024
EQNX::TICKER_START (NYSE:JNJ),(NASDAQ:CMPS),(NASDAQ:MNMD),(NASDAQ:ATAI),(NYSE:ABBV) EQNX::TICKER_END
Via
FinancialNewsMedia
How Psychedelic-Based Therapeutics Are Advancing in Treating Generalized Anxiety Disorder (GAD) Condition
January 24, 2024
EQNX::TICKER_START (NYSE:CYBN),(NASDAQ:CMPS),(NASDAQ:MNMD),(NASDAQ:SEEL),(NASDAQ:ATAI) EQNX::TICKER_END
Via
FinancialNewsMedia
Exposures
Product Safety
Compass Pathways appoints Teri Loxam as Chief Financial Officer
December 07, 2023
From
Compass Pathways
Via
GlobeNewswire
Study results of psilocybin treatment in bipolar II depression published in JAMA Psychiatry
December 06, 2023
Believed to be first ever psilocybin clinical trial for treatment of bipolar II depression
From
Compass Pathways
Via
GlobeNewswire
COMPASS Pathways Announces Third Quarter 2023 Financial Results and Business Highlights
November 02, 2023
From
COMPASS Pathways
Via
GlobeNewswire
COMPASS Pathways announces CFO transition
October 26, 2023
From
COMPASS Pathways
Via
GlobeNewswire
The Promise Of Psilocybin When It Comes To Mental Health, And How COMPASS Pathways (NASDAQ: CMPS) Is Advancing It
October 12, 2023
By Faith Ashmore, Benzinga
Via
TheNewswire.com
Exposures
Product Safety
How COMPASS Pathways Is Leveraging AI To Revolutionize The Mental Healthcare Space
September 22, 2023
By Faith Ashmore, Benzinga
Via
TheNewswire.com
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Product Safety
One Year Into Kabir Nath’s Leadership, Compass Pathways’ (NASDAQ: CMPS) Phase 3 Trial For Innovative Treatment Resistant Depression Progressing
September 19, 2023
By Faith Ashmore, Benzinga
Via
TheNewswire.com
Exposures
Product Safety
The Breakthrough Therapy Aiming To Solve The World’s Mental Health Crisis
September 19, 2023
EQNX::TICKER_START (NYSE:JNJ),(NYSE:ABBV),(NASDAQ:ATAI),(NASDAQ:CMPS),(NASDAQ:MNMD) EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Economy
Exposures
Economy
Product Safety
Global Psychedelic Therapeutics Market Size Expected To Reach $13.29 Billion By The Year 2031
July 26, 2023
EQNX::TICKER_START (NYSE:CYBN),NEO:CYBN),(NASDAQ:CMPS),(NASDAQ:MNMD),(NASDAQ:SEEL),(OTCQX:NUMIF) EQNX::TICKER_END
Via
FinancialNewsMedia
AMA Issues Details On First Psychedelics Therapy CPT Code – Thanks To These Psychedelic-Focused Mental Healthcare Companies
July 25, 2023
By Rachael Green, Benzinga
Via
TheNewswire.com
Exposures
Product Safety
Largest Phase 3 Clinical Trial on Psilocybin Gets Underway
June 09, 2023
Via
Investor Brand Network
COMPASS Pathways Announces First Quarter 2023 Financial Results and Business Highlights
May 11, 2023
From
COMPASS Pathways
Via
GlobeNewswire
American Medical Association to Issue First New Code for Psychedelic Therapies
May 02, 2023
COMPASS Pathways and MAPS PBC submitted joint application for new code to facilitate access to psychedelic therapy in the US, if approved
From
COMPASS Pathways
Via
GlobeNewswire
Compass Pathways Plc (NASDAQ: CMPS) Highlighted for Surprising Price Action
April 04, 2023
Via
Investor Brand Network
COMPASS Pathways Announces Fourth Quarter and Year-End 2022 Financial Results and Business Highlights
February 28, 2023
From
COMPASS Pathways
Via
GlobeNewswire
Psychedelic-Derived Medicines for Neurologic Conditions Fueling Large Revenue Growth in Projected $4 Billion Dollar Industry
January 26, 2023
EQNX::TICKER_START (OTCQB:LOBEF),(NASDAQ:ATAI),(NASDAQ:CMPS),(NYSE:CYBN),(NASDAQ:MNMD) EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Economy
Exposures
Supply Chain
COMPASS Pathways Announces Third Quarter 2022 Financial Results and Business Highlights
November 03, 2022
From
COMPASS Pathways
Via
GlobeNewswire
Psychedelic Drugs Prove Their Worth In Clinical Trials
October 11, 2022
Novel psychedelic drugs have continuously proven their worth in clinical trials. Just recently, one company revealed that it was in the process of finalizing its Phase 1 first-in-human clinical trial...
Via
PressReach
Atlanta Becomes Latest City to Consider Decriminalizing Psychedelics
September 22, 2022
Atlanta just became the latest city to consider decriminalizing psychedelics. On September 12, just one week after San Francisco officially decriminalized psychedelics, a meeting was held by the City...
Via
PressReach
Atlanta Becomes Latest City to Consider Decriminalizing Psychedelics
September 22, 2022
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – September 22, 2022 – Atlanta just became the latest city to consider decriminalizing psychedelics. On September 12, just one...
Via
FinancialNewsMedia
Psychedelics May Make People Less Afraid of Death
September 07, 2022
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – September 7, 2022 – According to a new survey by Johns Hopkins Medicine researchers, people’s attitudes toward death change...
Via
FinancialNewsMedia
Topics
Supply Chain
Exposures
Supply Chain
Compass Pathways to Begin New Phase 2 Psychedelic Trial for Anorexia
August 09, 2022
Via
Investor Brand Network
Ketamine Ushering in New Era in the Pharmacology Therapies for Neurological Disorders
July 27, 2022
Palm Beach, FL – July 27, 2022 – For years, ketamine was known for its use as an anesthetic or as a recreational drug. Its ability to provide quick and safe sedation saved many lives during the Vietnam...
Via
FinancialNewsMedia
Topics
Law Enforcement
Exposures
Legal
Appeal Board Upholds Compass Pathways’ Patent on Synthetic Psilocybin Formulation
June 30, 2022
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
World’s Richest Man Says Psychedelics Could Make a Real Difference in Mental Health
June 15, 2022
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – June 15, 2022 – Elon Musk believes that psychedelics and other plant-based drugs are better than pharma meds in treating a...
Via
FinancialNewsMedia
Rising Cases Of Mental Health Disorders of Stress, Anxiety & Addiction Fueling Need for Central Nervous System Therapeutics
June 07, 2022
Palm Beach, FL – June 7, 2022 – FinancialNewsMedia.com News Commentary – The global Central Nervous System (CNS) treatments and its market revenues had been steadily growing pre-pandemic and are still...
Via
FinancialNewsMedia
Exposures
COVID-19
Compass Pathways Research Suggests Psilocybin Can Treat Anorexia
May 12, 2022
Via
Investor Brand Network
Oregon to Become the First State to Legally Roll Out Psilocybin
April 28, 2022
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – April 28, 2022 – Oregon is set to become the first US state to market legal psilocybin, the psychoactive substance found in...
Via
FinancialNewsMedia
Topics
Derivatives
ETFs
Exposures
Derivatives
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.